Detalles de la búsqueda
1.
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
J Eur Acad Dermatol Venereol
; 38(5): 864-872, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38179809
2.
Insurance coverage and financing landscape for HIV treatment and prevention in the USA.
Lancet
; 397(10279): 1127-1138, 2021 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33617778
3.
Emerging Lessons and Policy Options for Sexually Transmitted Infection Telehealth Payment: A Narrative Review.
Sex Transm Dis
; 49(11S Suppl 2): S26-S30, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35617528
4.
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Lancet
; 394(10198): 576-586, 2019 08 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31280967
5.
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
N Engl J Med
; 375(5): 422-34, 2016 Aug 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27518661
6.
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
N Engl J Med
; 373(14): 1318-28, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26422722
7.
The Importance of Structural Interventions for Advancing Sexual Health and Health Equity in the United States: A Review of the Evidence and Recommendations for Action on Sexually Transmitted Infections.
Sex Transm Dis
; 50(1): 1-4, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35969841
8.
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
Br J Dermatol
; 189(1): 132-134, 2023 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36944555
9.
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
J Am Acad Dermatol
; 78(1): 90-99.e1, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28993005
10.
Ending the HIV epidemic in US Latinx sexual and gender minorities.
Lancet
; 397(10279): 1043-1045, 2021 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33617767
11.
From COVID-19 to Monkeypox: Unlearned Lessons for Black, Latino, and Other Men With HIV Who Have Sex With Men.
Am J Public Health
; 112(11): 1567-1571, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36108251
12.
Preventing HIV and Hepatitis Infections Among People Who Inject Drugs: Leveraging an Indiana Outbreak Response to Break the Impasse.
AIDS Behav
; 21(4): 968-972, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28220312
13.
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
J Am Acad Dermatol
; 77(2): 310-317.e1, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28416342
14.
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Ann Rheum Dis
; 75(6): 1065-73, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26792812
15.
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
J Am Acad Dermatol
; 74(1): 134-42, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26549249
16.
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
Dermatol Ther (Heidelb)
; 14(2): 441-451, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38332436
17.
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
J Dermatolog Treat
; 33(7): 2991-2996, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35839335
18.
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Dermatol Ther (Heidelb)
; 12(2): 561-575, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35050485
19.
Strategies for Health System Innovation After Gobeille v Liberty Mutual Insurance Company.
JAMA
; 316(6): 581-2, 2016 Aug 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27367856
20.
A brief guide to pustular psoriasis for primary care providers.
Postgrad Med
; 133(3): 330-344, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33118424